You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Vancouver, Canada and Deerfield, Illinois, USA, August 11, 2008 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. (“Astellas”) today...
Read more about Cardiome and Astellas Announce Receipt of FDA Approvable Letter for Kynapid™
First A2A Adenosine Receptor Agonist Approved for Use in Identifying Coronary Artery Disease Deerfield, Ill., June 24, 2008 – Astellas Pharma US, Inc. today announced the commercial availability...
First A2A Adenosine Receptor Agonist Approved for Use as Pharmacologic Stress Agent in Myocardial Perfusion Imaging PALO ALTO, Calif. and DEERFIELD, Ill., April 10 /PRNewswire-FirstCall/ -- CV...
Deerfield, Illinois and Vancouver, Canada, March 25, 2008 -- Astellas Pharma US, Inc. and its co-development partner Cardiome Pharma Corp. announced the first pivotal Phase III study evaluating...
MELVILLE, N.Y.--(BUSINESS WIRE)--Feb. 27, 2008--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that it has filed with the U.S. Patent and Trademark Office an application to reissue its...
Follow U.S. news
